Jeffrey Albers made president of Algeta US
This article was originally published in Scrip
Algeta has appointed Jeffrey Albers president of Algeta US, the company's new US commercial operation. Mr Albers will report to Andrew Kay, Algeta's president and CEO, and will work with senior management to build the US operations, including a sales and marketing force ahead of the launch of Alpharadin (radium-223 chloride; pending approval), Algeta's lead product for the treatment of castration-resistant prostate cancer. Mr Albers most recently served as vice-president of Genzyme's US haematology and oncology business, having worked at Genzyme for seven years.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.